Big Pharmas team to tackle trial bottlenecks
The new organisation - Transcelerate BioPharma - was launched at a conference in the US last week with the aim of sharing research and solutions that will “simplify and accelerate the delivery of exciting new medicines for patients” according to CEO Garry Neil.
“We aim to reduce bottlenecks in R&D and increase efficiency. This is all about accelerating transformative innovation. We have an obligation to stakeholders to find…new and transformative ways of doing things. We are really working collectively in a way we haven’t done before,” he added.
According to a Forbes report members including Abbott, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, J&J, Pfizer, Genentech and Sanofi will focus their efforts on clinical trials, ranging from the development of standards for data and risk assessment to establishing training best practices for physicians.
